Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The low and middle income countries opioid substitution therapy market is expected to develop at a CAGR of 7.4% during the forecast period. The market value is projected to increase from US$ 805.2 million in 2024 to US$ 1,622.1 million by 2034. The low and middle income countries opioid substitution therapy market is valued at US$ 750.2 million at the end of 2023.
Key Highlight
Attributes | Details |
---|---|
Estimated Market Size, 2024 | US$ 805.2 million |
Expected Market Size, 2034 | US$ 1,622.1 million |
Value CAGR (2024 to 2034) | 7.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Opioid substitution therapy has emerged as a crucial evidence-based approach for effectively managing opioid dependence. It is gaining increasing prominence in low and middle income countries (LMICs). The choice of drugs for this therapy varies across countries, contingent upon prescription regulations and approvals from relevant regulatory bodies.
Buprenorphine and methadone have garnered widespread acceptance as the treatment of choice, primarily attributed to their availability in diverse formulations, strengths, and brands. It's noteworthy that naloxone and naltrexone, both serving as opioid blockers, play distinct roles in the spectrum of substance use disorder management.
Naloxone, with its rapid-acting nature, is designed as an emergency intervention to reverse the effects of opioid overdose swiftly. Conversely, naltrexone assumes a different role. It is not intended for overdose situations. Instead, it is prescribed as a daily or monthly medication for addressing alcohol use disorder or opioid use disorder as part of ongoing treatment.
Naloxone functions as a critical tool for emergency scenarios, providing rapid response in overdose situations. On the other hand, naltrexone serves as a maintenance medication for the sustained treatment of substance use disorders. The introduction of generic and over-the-counter (OTC) products is poised to enhance accessibility to appropriate treatment, contributing to a forecasted reduction in mortality rates. This development marks a significant stride toward ensuring effective and accessible solutions in the landscape of opioid dependence management.
The low and middle-income countries' opioid substitution therapy market recorded a historic CAGR of 5.1% in the last five years from 2019 to 2023.
Opioid use disorder (OUD) stands as a significant global health challenge, contributing to heightened rates of premature mortality and morbidity. Within the framework of comprehensive OUD treatment (OUDT), opioid substitution therapy has gained approval. Opioid use disorders have a significant global impact, affecting over 16 million individuals. The prevalence of opioid use and dependency exhibits variations based on age and gender. Opioid-related deaths are more prevalent in older age groups, particularly between the ages of 40 and 50. However, heroin overdoses peak among individuals aged 20 to 30.
Attributes | Details |
---|---|
Low and Middle Income Countries Opioid Substitution Therapy Market Size, 2023 | US$ 750.2 million |
The widespread prevalence of chronic pain and the concurrent issue of prescription opioid abuse have significant implications for patients, healthcare providers, and society at large. Opioid treatment programs (OTPs) play a vital role in addressing these challenges by offering medication-assisted treatment (MAT) for individuals diagnosed with opioid use disorder (OUD). Increasing prevalence and awareness stand out as crucial factors propelling market growth in low and middle-income countries.
Companies dedicated to opioid substitution therapy are actively developing and introducing novel goods and technologies. They aim to improve accessibility to treatment and diagnostic procedures in low and middle-income countries. This trend has resulted in an increased demand for opioid substitution therapy.
The evolution of therapeutic molecules goes hand in hand with advancements in drug delivery technologies. Innovative delivery systems bring a host of advantages to the medical field. These include enhanced bioavailability, making them well-suited for the long-term treatment of chronic illnesses. Additionally, such systems contribute to sustained maintenance of drug levels, reduced adverse effects, lower dosage requirements, improved patient compliance, minimized damage to healthy tissues, and the potential for cost reductions by developing new delivery systems for existing molecules. Currently, trending drug delivery mechanisms include implants, self-injectable, prefilled syringes, injectable pens, and others.
Over the past decade, a lot of innovation has occurred in injectable therapeutics. For instance, notable manufacturer Rusan Pharma introduced a wide range of product offerings in opioid substitution therapy, one of which is Verso (Naloxone), which is available in prefilled, injectable pen and vial forms.
The emergence of this innovative drug delivery technology and formulations presents promising business prospects for the opioid substitution therapy market in low and middle income countries.
The unmet medical needs in rural areas underscore the pressing necessity for improved healthcare access and resources, highlighting disparities that must be addressed to ensure comprehensive and equitable healthcare coverage. In rural parts, substance use patterns show higher rates of tobacco and methamphetamine use among adults, while opioid use has proliferated in towns of varying sizes.
Rural adolescents and young adults tend to exhibit elevated rates of alcohol consumption and engage in risky behaviors like binge drinking and driving under the influence more frequently than their urban counterparts. The battle against substance use in rural communities is complicated by resource limitations for prevention, treatment, and recovery. Multiple factors contribute to this situation, such as limited access to education, financial hardships, joblessness, inadequate availability of mental health support, experiences of isolation and despair, and higher societal stigma around mental health and substance use issues.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The dynamics of the global low and middle income countries opioid substitution therapy market could be influenced by related markets in healthcare, such as the opioid use disorder treatment market and bipolar disorder drugs and treatment market. A thorough examination of these sectors can furnish valuable insights, serving as a foundation for crafting strategies that drive growth and uncover opportunities within the low and middle income countries' opioid substitution therapy market.
Exploring these related industries in-depth can yield profound insights. This is likely to enable the formulation of distinctive strategies to pursue growth and capitalize on opportunities within the opioid substitution therapy market in low and middle income countries. For instance, understanding the nuances of the opioid use disorder treatment market may unveil potential collaborative initiatives with existing treatment providers or highlight gaps in accessibility that could be addressed through strategic partnerships.
Global Low and Middle Income Countries Opioid Substitution Therapy Market:
Attributes | Low and Middle Income Countries Opioid Substitution Therapy Market |
---|---|
CAGR (2024 to 2034) | 7.4% |
Growth Factor | Supportive policies and funding for addiction treatment |
Key Trend | The integration of telemedicine in OST allows for remote monitoring and support |
Global Opioid Use Disorder Treatment Market:
Attributes | Opioid Use Disorder Treatment Market |
---|---|
CAGR (2024 to 2034) | 10.5% |
Growth Factor | Broader insurance coverage for addiction treatment |
Key Trend | Growing acceptance and utilization of medication-assisted treatment |
Global Bipolar Disorder Drugs and Treatment Market:
Attributes | Bipolar Disorder Drugs and Treatment Market |
---|---|
CAGR (2024 to 2034) | 2.72% |
Growth Factor | Exploration of combination therapies to address the complex nature |
Key Trend | Integration of digital tools and apps to support cognitive behavioral therapy |
Countries | CAGR from 2024 to 2034 |
---|---|
Brazil | 3.0% |
China | 8.4% |
India | 4.1% |
Malaysia | 13.6% |
Georgia | 14.3% |
Brazil dominated the low and middle-income market as of 2023. With the anticipation of sustaining this momentum, Brazil is expected to demonstrate persistent high growth throughout the forecast period.
Over the past four decades, Brazil has witnessed a steady rise in urban violence and crime, a trend persisting despite positive strides in the nation's social and economic conditions. This surge is closely connected to the escalating domestic drug consumption, prompting significant shifts in the structure, profile, and modus operandi of organized crime groups. The intertwining issues of violence and criminality find a nexus in the operations of organized crime groups engaged in arms and drug trafficking.
Brazil, currently hosting the world's fourth-leading incarcerated population, underscores the urgency for alternative approaches to address the complex challenges of violence and crime, especially in the context of drug consumption. Efforts to navigate these issues require a comprehensive strategy that considers the interconnected factors contributing to the intricate landscape of crime and violence in the country.
In 2023, India held dominant revenue in the low and middle-income market, contributing around US$ 87.25 million.
About 2.1% of India's population is grappling with opioid use, encompassing substances like opium and its derivatives such as poppy husk, heroin (or its impure forms like smack or brown sugar), and various pharmaceutical opioids. Nationally, heroin emerges as a widespread opioid (1.14%), followed by pharmaceutical opioids (0.96%) and opium (0.52%). Notably, Nagaland, Arunachal Pradesh, Manipur, Sikkim, and Mizoram exhibit the highest prevalence of opioid use among the general population, surpassing 10%. The growing concern surrounding opioid consumption in India necessitates targeted interventions and public health initiatives to address the escalating trend.
Georgia's healthcare system benefits significantly from its access to healthcare supplies and assistance provided by established European countries. This collaboration fosters the exchange of medical resources, expertise, and support, enhancing Georgia's ability to address healthcare challenges effectively. This interconnected network of support reflects a commitment to regional health cooperation and underscores the importance of collective efforts in promoting the well-being of populations across borders.
Drug Class | CAGR from 2024 to 2034 |
---|---|
Opioid Antagonists | 9.4% |
Opioid Agonists and Partial Agonists | 6.6% |
The market value of opioid agonists and partial agonists in low and middle-income countries for opioid substitution therapy is US$ 588.5 million, representing a sizable 73.6% market share in 2023. The credibility of the drug's mode of action plays a pivotal role. Given its comparatively lower efficacy, buprenorphine is widely suitable for individuals with mild to moderate dependence. In contrast, methadone is applicable across all levels of support.
Indication | CAGR from 2024 to 2034 |
---|---|
Pain Management | 13.1% |
Opioid Withdrawal/Opioid Use Disorder (OUD) | 6.5% |
The market value of opioid withdrawal/opioid use disorder (OUD) in low and middle-income countries for opioid substitution therapy is US$ 649.2 million, representing a sizable 86.6% market share in 2023. The prevalence of opioid use disorders, along with the complex nature of withdrawal symptoms, underscores the urgency and necessity of effective interventions and treatments within the broader healthcare landscape. As a result, the demand for solutions addressing opioid withdrawal and use disorder remains high, making it a dominant component in the spectrum of pain management, alcohol de-addiction, and mental health care.
Distribution Channel | CAGR from 2024 to 2034 |
---|---|
Government-supported Centers/NGO’s/Tenders | 6.3% |
Institutional Sales | 10.2% |
The government-supported centers/NGOs/tenders have a considerable presence in the low and middle-income countries' opioid substitution therapy market, accounting for 80.5% of end users in 2023. The elevated significance of government-supported centers/NGOs/tenders in claiming the highest share stems from their crucial role in extending treatment accessibility at reduced costs. Additionally, entities funded through these channels often can provide treatment at no cost, further emphasizing their central role in ensuring widespread and affordable healthcare options.
Market players commit resources to advance research and development, aiming to integrate innovative features, technologies, and improvements into their opioid substitution therapy. Furthermore, industry players strategically emphasize expanding their influence in key geographic regions. This strategic expansion entails initiatives such as establishing new distribution channels, fostering partnerships with local distributors, or setting up subsidiaries in strategically advantageous locations for the effective distribution and accessibility of opioid substitution therapy solutions.
Attribute | Details |
---|---|
Forecast Period | 2024 to 2034 |
Historical Data Available for | 2018 to 2023 |
Market Analysis | US$ million for Value |
Key Regions Covered | Latin America, China, South Asia and Pacific, Europe, Arica, Central Asia |
Key Countries Covered | Brazil, Peru, China, India, Vietnam, Afghanistan, Bangladesh, Cambodia, Myanmar, Nepal, Pakistan, Malaysia, Thailand, Ukraine, Georgia, Armenia, Kyrgyzstan, Kazakhstan, Tajikistan, South Africa, Nigeria, Egypt, Tanzania, Ghana, Kenya, Mozambique, Senegal, Uganda, Côte d'Ivoire (Ivory Coast), and the Rest of the low and middle income countries |
Key Market Segments Covered | Drug Class, Indication, Distribution Channel, and Region |
Key Companies Profiled |
|
Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
Pricing | Available upon Request |
The market is currently valued at around US$ 750.2 million in 2023.
The market is set to reach a valuation of around US$ 1,622.1 million by the end of 2034.
The opioid and partial agonists segment, within the drug class segment, held a 73.6% market share in 2023.
Demand for opioid substitution therapy in low and middle income countries increased at a 5.1% CAGR from 2019 to 2023.
The estimated market value for 2024 is around US$ 805.2 million.
Brazil accounts for around 13.8% share of the market in 2023.
India holds about 11.6% market share in the market in 2023.
Georgia accounted for a market value share of around 1.9% in 2023.
1. Market Overview 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Development/Innovation Trends 4. Value-Added Insights 4.1. Opioid Use Disorder and Global Overview 4.2. Disease Epidemiology Data, By Region 4.3. Drug Adoption / Usage Analysis, by Region 4.4. Pipeline Assessment 4.5. Singular Breakthroughs of Buprenorphine 4.6. Regulations Landscape 4.7. PESTEL Analysis 4.8. Porter’s Analysis 4.9. Value Chain Analysis, By Region 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. R&D funding By Region 5.1.3. R&D funding By Country 5.1.4. Pharmaceutical Spending 5.1.5. Expenditure on Retail Pharmaceuticals Per Capita 5.1.6. Parent Market Analysis 5.2. Forecast Factors - Relevance & Impact 5.2.1. Recent Developments In Management of Opioid Use 5.2.2. Rising Prevalence of OUD 5.2.3. Treatment Seeking Rate 5.2.4. High Unmet Medical Needs 5.2.5. Illicit Drug Dependence or Abuse 5.2.6. Ongoing Active Clinical Trials 5.2.7. Increasing Number of Programs 5.2.8. Regulatory Scenario 5.2.9. Diagnosis Rate 5.2.10. Drug Delivery Technology 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Market Demand (in Volume (Units) Analysis 2018 to 2023 and Forecast, 2024 to 2034 6.1. Historical Market Volume (Units) Analysis, 2018 to 2023 6.2. Current and Future Market Volume (Units) Projections, 2024 to 2034 6.2.1. Y-o-Y Growth Trend Analysis 7. Market – Pricing Assessment 7.1. Regional Pricing Analysis, By Product 7.2. Pricing Break-up 7.2.1. Manufacturer Level Pricing 7.2.2. Distributor Level Pricing 7.3. Global Average Pricing Analysis Benchmark, By Product 7.3.1. Pricing Assumptions 8. Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2023 and Forecast, 2024 to 2034 8.1. Revenue Opportunity Analysis 8.2. Historical Market Value (US$ Million) and Volume (Unit) Analysis, 2018 to 2023 8.3. Current and Future Market Value (US$ Million) and Volume (Unit) Projections, 2024 to 2034 8.3.1. Y-o-Y Growth Trend Analysis 8.3.2. Absolute $ Opportunity Analysis 9. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Drug Class 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) & Market Volume(Unit) Analysis, By Drug Class, 2018 to 2023 9.3. Current and Future Market Size (US$ Million) & Market Volume(Unit) and Forecast By Drug Class, 2024 to 2034 9.3.1. Opioid Antagonists 9.3.1.1. Naltrexone 9.3.1.2. Naloxone 9.3.2. Opioid Agonists and Partial Agonists 9.3.2.1. Methadone 9.3.2.2. Buprenorphine 9.4. Market Attractiveness Analysis By Drug Class 10. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) By Indication, 2018 to 2023 10.3. Current and Future Market Size (US$ Million) and Analysis and Forecast By Indication, 2024 to 2034 10.3.1. Pain Management 10.3.2. Opioid Withdrawal/Opioid Use Disorder (OUD) 10.3.3. Alcohol De-addiction 10.3.4. Depression 10.4. Market Attractiveness Analysis By Indication 11. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Distribution Channel 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) By Distribution Channel, 2018 to 2023 11.3. Current and Future Market Size (US$ Million) and Analysis and Forecast By Distribution Channel, 2024 to 2034 11.3.1. Government Supported Centers/NGO’s/Tenders 11.3.2. Institutional Sales 11.3.2.1. Hospitals 11.3.2.1.1. Private Hospitals 11.3.2.1.2. Public Hospitals 11.3.2.2. Psychiatric clinics 11.3.2.2.1. Private Clinics 11.3.2.2.2. Public Clinics 11.3.3. Retail Sales 11.3.3.1. Retail Pharmacies 11.3.3.2. Drug Store 11.3.3.3. Online Sales/Mail Order Pharmacies 11.4. Market Attractiveness Analysis By Distribution Channel 12. Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Trend Analysis by Region, 2018 to 2023 12.3. Current and Future Market Size (US$ Million) and Forecast by Region, 2024 to 2034 12.3.1. Latin America 12.3.2. Europe 12.3.3. China 12.3.4. Central Asia 12.3.5. South Asia and Pacific 12.3.6. Middle East and Africa 12.4. Market Attractiveness Analysis by Region 13. Latin America Market Analysis 2018 to 2023 and Forecast 2024 to 2034 13.1. Introduction 13.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023 13.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Peru 13.3.1.3. Rest of Latin America 13.3.2. By Drug Class 13.3.3. By Indication 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Indication 13.4.4. By Distribution Channel 13.5. Drivers & Restraints Impact Analysis 13.6. Country-Wise Analysis 13.6.1. Brazil Market Analysis 13.6.1.1. Introduction 13.6.1.2. Market Analysis and Forecast by Market Taxonomy 13.6.1.2.1. By Drug Class 13.6.1.2.2. By Indication 13.6.1.2.3. By Distribution Channel 13.6.2. Peru Market Analysis 13.6.2.1. Introduction 13.6.2.2. Market Analysis and Forecast by Market Taxonomy 13.6.2.2.1. By Drug Class 13.6.2.2.2. By Indication 13.6.2.2.3. By Distribution Channel 13.6.3. Rest of Latin America Market Analysis 13.6.3.1. Introduction 13.6.3.2. Market Analysis and Forecast by Market Taxonomy 13.6.3.2.1. By Drug Class 13.6.3.2.2. By Indication 13.6.3.2.3. By Distribution Channel 14. China Market Analysis 2018 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023 14.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034 14.3.1. By Drug Class 14.3.2. By Indication 14.3.3. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Drug Class 14.4.2. By Indication 14.4.3. By Distribution Channel 14.5. Drivers & Restraints Impact Analysis 15. South Asia and Pacific Market Analysis 2018 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023 15.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Malaysia 15.3.1.4. Vietnam 15.3.1.5. Afghanistan 15.3.1.6. Bangladesh 15.3.1.7. Cambodia 15.3.1.8. Myanmar 15.3.1.9. Nepal 15.3.1.10. Pakistan 15.3.2. By Drug Class 15.3.3. By Indication 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Indication 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Drivers & Restraints Impact Analysis 15.7. Key Market Players Intensity Mapping 15.8. PESTEL Analysis 15.9. Country-Wise Analysis 15.9.1. India Market Analysis 15.9.1.1. Introduction 15.9.1.2. Market Analysis and Forecast by Market Taxonomy 15.9.1.2.1. By Drug Class 15.9.1.2.2. By Indication 15.9.1.2.3. By Distribution Channel 15.9.2. Thailand Market Analysis 15.9.2.1. Introduction 15.9.2.2. Market Analysis and Forecast by Market Taxonomy 15.9.2.2.1. By Drug Class 15.9.2.2.2. By Indication 15.9.2.2.3. By Distribution Channel 15.9.3. Malaysia Market Analysis 15.9.3.1. Introduction 15.9.3.2. Market Analysis and Forecast by Market Taxonomy 15.9.3.2.1. By Drug Class 15.9.3.2.2. By Indication 15.9.3.2.3. By Distribution Channel 15.9.4. Vietnam Market Analysis 15.9.4.1. Introduction 15.9.4.2. Market Analysis and Forecast by Market Taxonomy 15.9.4.2.1. By Drug Class 15.9.4.2.2. By Indication 15.9.4.2.3. By Distribution Channel 15.9.5. Afghanistan Market Analysis 15.9.5.1. Introduction 15.9.5.2. Market Analysis and Forecast by Market Taxonomy 15.9.5.2.1. By Drug Class 15.9.5.2.2. By Indication 15.9.5.2.3. By Distribution Channel 15.9.6. Bangladesh Market Analysis 15.9.6.1. Introduction 15.9.6.2. Market Analysis and Forecast by Market Taxonomy 15.9.6.2.1. By Drug Class 15.9.6.2.2. By Indication 15.9.6.2.3. By Distribution Channel 15.9.7. Cambodia Market Analysis 15.9.7.1. Introduction 15.9.7.2. Market Analysis and Forecast by Market Taxonomy 15.9.7.2.1. By Drug Class 15.9.7.2.2. By Indication 15.9.7.2.3. By Distribution Channel 15.9.8. Myanmar Market Analysis 15.9.8.1. Introduction 15.9.8.2. Market Analysis and Forecast by Market Taxonomy 15.9.8.2.1. By Drug Class 15.9.8.2.2. By Indication 15.9.8.2.3. By Distribution Channel 15.9.9. Nepal Market Analysis 15.9.9.1. Introduction 15.9.9.2. Market Analysis and Forecast by Market Taxonomy 15.9.9.2.1. By Drug Class 15.9.9.2.2. By Indication 15.9.9.2.3. By Distribution Channel 15.9.10. Pakistan Market Analysis 15.9.10.1. Introduction 15.9.10.2. Market Analysis and Forecast by Market Taxonomy 15.9.10.2.1. By Drug Class 15.9.10.2.2. By Indication 15.10. By Distribution Channel 16. Europe Market Analysis 2018 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023 16.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. Ukraine 16.3.1.2. Armenia 16.3.1.3. Georgia 16.3.2. By Drug Class 16.3.3. By Indication 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Indication 16.4.4. By Distribution Channel 16.5. Drivers & Restraints Impact Analysis 16.6. Country-Wise Analysis 16.6.1. Ukraine Market Analysis 16.6.1.1. Introduction 16.6.1.2. Market Analysis and Forecast by Market Taxonomy 16.6.1.2.1. By Drug Class 16.6.1.2.2. By Indication 16.6.1.2.3. By Distribution Channel 16.6.2. Armenia Market Analysis 16.6.2.1. Introduction 16.6.2.2. Market Analysis and Forecast by Market Taxonomy 16.6.2.2.1. By Drug Class 16.6.2.2.2. By Indication 16.6.2.2.3. By Distribution Channel 16.6.3. Georgia Market Analysis 16.6.3.1. Introduction 16.6.3.2. Market Analysis and Forecast by Market Taxonomy 16.6.3.2.1. By Drug Class 16.6.3.2.2. By Indication 16.6.3.2.3. By Distribution Channel 17. Central Asia Market Analysis 2018 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023 17.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034 17.3.1. By Country 17.3.1.1. Kazakhstan 17.3.1.2. Kyrgyzstan 17.3.1.3. Tajikistan 17.3.1.4. Rest of Central Asia 17.3.2. By Drug Class 17.3.3. By Indication 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Indication 17.4.4. By Distribution Channel 17.5. Drivers & Restraints Impact Analysis 17.6. Country-Wise Analysis 17.6.1. Kazakhstan Market Analysis 17.6.1.1. Introduction 17.6.1.2. Market Analysis and Forecast by Market Taxonomy 17.6.1.2.1. By Drug Class 17.6.1.2.2. By Indication 17.6.1.2.3. By Distribution Channel 17.6.2. Kyrgyzstan Market Analysis 17.6.2.1. Introduction 17.6.2.2. Market Analysis and Forecast by Market Taxonomy 17.6.2.2.1. By Drug Class 17.6.2.2.2. By Indication 17.6.2.2.3. By Distribution Channel 17.6.3. Tajikistan Market Analysis 17.6.3.1. Introduction 17.6.3.2. Market Analysis and Forecast by Market Taxonomy 17.6.3.2.1. By Drug Class 17.6.3.2.2. By Indication 17.6.3.2.3. By Distribution Channel 18. Africa Market Analysis 2018 to 2023 and Forecast 2024 to 2034 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023 18.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034 18.3.1. By Country 18.3.1.1. Kenya 18.3.1.2. Egypt 18.3.1.3. South Africa 18.3.1.4. Nigeria 18.3.1.5. Cote d'Ivoire 18.3.1.6. Ghana 18.3.1.7. Mozambique 18.3.1.8. Senegal 18.3.1.9. Tanzania 18.3.1.10. Uganda 18.3.2. By Drug Class 18.3.3. By Indication 18.3.4. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Indication 18.4.4. By Distribution Channel 18.5. Drivers & Restraints Impact Analysis 18.6. Country Level Analysis 18.6.1. Kenya Market Analysis 18.6.1.1. Introduction 18.6.1.2. Market Analysis and Forecast by Market Taxonomy 18.6.1.2.1. By Drug Class 18.6.1.2.2. By Indication 18.6.1.2.3. By Distribution Channel 18.6.2. Egypt Market Analysis 18.6.2.1. Introduction 18.6.2.2. Market Analysis and Forecast by Market Taxonomy 18.6.2.2.1. By Drug Class 18.6.2.2.2. By Indication 18.6.2.2.3. By Distribution Channel 18.6.3. South Africa Market Analysis 18.6.3.1. Introduction 18.6.3.2. Market Analysis and Forecast by Market Taxonomy 18.6.3.2.1. By Drug Class 18.6.3.2.2. By Indication 18.6.3.2.3. By Distribution Channel 18.6.4. Nigeria Market Analysis 18.6.4.1. Introduction 18.6.4.2. Market Analysis and Forecast by Market Taxonomy 18.6.4.2.1. By Drug Class 18.6.4.2.2. By Indication 18.6.4.2.3. By Distribution Channel 18.6.5. Cote d'Ivoire Market Analysis 18.6.5.1. Introduction 18.6.5.2. Market Analysis and Forecast by Market Taxonomy 18.6.5.2.1. By Drug Class 18.6.5.2.2. By Indication 18.6.5.2.3. By Distribution Channel 18.6.6. Ghana Market Analysis 18.6.6.1. Introduction 18.6.6.2. Market Analysis and Forecast by Market Taxonomy 18.6.6.2.1. By Drug Class 18.6.6.2.2. By Indication 18.6.6.2.3. By Distribution Channel 18.6.7. Mozambique Market Analysis 18.6.7.1. Introduction 18.6.7.2. Market Analysis and Forecast by Market Taxonomy 18.6.7.2.1. By Drug Class 18.6.7.2.2. By Indication 18.6.7.2.3. By Distribution Channel 18.6.8. Senegal Market Analysis 18.6.8.1. Introduction 18.6.8.2. Market Analysis and Forecast by Market Taxonomy 18.6.8.2.1. By Drug Class 18.6.8.2.2. By Indication 18.6.8.2.3. By Distribution Channel 18.6.9. Tanzania Market Analysis 18.6.9.1. Introduction 18.6.9.2. Market Analysis and Forecast by Market Taxonomy 18.6.9.2.1. By Drug Class 18.6.9.2.2. By Indication 18.6.9.2.3. By Distribution Channel 18.6.10. Uganda Market Analysis 18.6.10.1. Introduction 18.6.10.2. Market Analysis and Forecast by Market Taxonomy 18.6.10.2.1. By Drug Class 18.6.10.2.2. By Indication 18.6.10.2.3. By Distribution Channel 19. Rest of Countries Market Analysis 2018–2023 and Forecast 2024 to 2034 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Unit) Trend Analysis by Market Taxonomy, 2018 to 2023 19.3. Current and Future Market Size (US$ Million) and Volume (Unit) Forecast by Market Taxonomy, 2024 to 2034 19.3.1. By Drug Class 19.3.2. By Indication 19.3.3. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug Class 19.4.3. By Indication 19.4.4. By Distribution Channel 19.5. Drivers & Restraints Impact Analysis 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players (%) 20.3. Market Presence Analysis 20.3.1. Regional footprint of Players 20.3.2. Platform Type foot print by Players 20.3.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Branding and Promotional Strategies, By Key Manufactures 21.4. Key Development Analysis 21.5. Competition Deep Dive 21.5.1. Pfizer Inc. 21.5.1.1. Overview 21.5.1.2. Drug Pipeline Portfolio 21.5.1.3. Key Financials 21.5.1.4. SWOT Analysis 21.5.1.5. Key Developments 21.5.1.6. Sales Footprint 21.5.1.7. Strategy Overview 21.5.1.7.1. Marketing Strategy 21.5.1.7.2. Product Strategy 21.5.1.7.3. Channel Strategy 21.5.2. Takeda Pharmaceuticals 21.5.3. Alkermes, Inc 21.5.4. Hikma Pharmaceuticals 21.5.5. Emergent BioSolutions Inc. 21.5.6. Indivior Inc. 21.5.7. Mundipharma GmbH 21.5.8. Purdue Pharma LP 21.5.9. Orexo US, Inc. 21.5.10. Boehringer Ingelheim 21.5.11. Jamp Pharma Corporation 21.5.12. Vistapharm, Inc. 21.5.13. Atlantic Biologicals Corp. 21.5.14. BLISTECO S.A.S. 21.5.15. BioDelivery Sciences International Inc 21.5.16. Purdue Pharma 21.5.17. Braeburn Inc. 21.5.18. Camurus Ab 21.5.19. Knight Therapeutics Inc. 21.5.20. Titan Pharmaceuticals, Inc. 21.5.21. Braeburn Pharmaceuticals 21.5.22. L. Molteni & C. Dei Fratelli Alitti Società Di Esercizio S.P.A. 21.5.23. Sterinova Inc 21.5.24. Teva Pharmaceutical Industries Ltd. 21.5.25. USWM, LLC. 21.5.26. Wellona Pharma 21.5.27. Taj Pharmaceuticals Limited 21.5.28. Livealth Biopharma Pvt Ltd 21.5.29. Somerset Therapeutics Limited 21.5.30. Walter Healthcare Private Limited 21.5.31. Mallinckrodt Pharmaceuticals 21.5.32. Rusan Pharma Ltd 21.5.33. Viatris Inc 21.5.34. RINQUE PHARMA. 21.5.35. Par Pharmaceutical 21.5.36. The Bristol-Myers Squibb Company 21.5.37. Intas Pharmaceuticals 21.5.38. STERIS PHARMA 22. Assumptions and Acronyms Used 23. Research Methodology
Recommendations
Explore Healthcare Insights
View Reports